These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 3288868

  • 1. The crisis in clinical cancer research. Third-party insurance and investigational therapy.
    Antman K, Schnipper LE, Frei E.
    N Engl J Med; 1988 Jul 07; 319(1):46-8. PubMed ID: 3288868
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness and reimbursement in patient care.
    Antman KH, Aledort LM, Yarbro J, Wilensky G, Wojcik S, Monaco GP, Windham S.
    Semin Hematol; 1989 Jul 07; 26(3 Suppl 3):32-45. PubMed ID: 2508228
    [Abstract] [Full Text] [Related]

  • 7. Ethical and financial considerations in third-party support of investigational cancer therapies.
    Young FE.
    Cancer; 1993 Nov 01; 72(9 Suppl):2854-8. PubMed ID: 8402519
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Third party reimbursement for participation in cancer clinical trials: a proposal for legislation.
    Plaue GM.
    J Contemp Health Law Policy; 2000 Nov 01; 16(2):305-54. PubMed ID: 10921232
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Who pays for clinical research?
    Weiss GB.
    Clin Res; 1979 Oct 01; 27(4):297-9. PubMed ID: 10309043
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Medicare reimbursement for clinical trial services: understanding Medicare coverage in establishing a clinical trial budget.
    Barnes M, Korn J.
    J Health Law; 2005 Oct 01; 38(4):609-31. PubMed ID: 16673632
    [Abstract] [Full Text] [Related]

  • 15. Hospitals try to devise solutions in device debate.
    Scott L.
    Mod Healthc; 1995 Feb 20; 25(8):34-6, 38. PubMed ID: 10140204
    [Abstract] [Full Text] [Related]

  • 16. Reimbursement issues facing patients, providers, and payers.
    Antman K.
    Cancer; 1993 Nov 01; 72(9 Suppl):2842-5. PubMed ID: 8402516
    [Abstract] [Full Text] [Related]

  • 17. Experimental therapy--who shall pay?
    N Engl J Med; 1991 May 02; 324(18):1291-2. PubMed ID: 2014045
    [No Abstract] [Full Text] [Related]

  • 18. Gore champions major new cancer initiative.
    Castellucci L.
    J Natl Cancer Inst; 1998 Feb 18; 90(4):270. PubMed ID: 9486811
    [No Abstract] [Full Text] [Related]

  • 19. The need for Diagnosis-Related Group 471. Protection for clinical research.
    Yarbro JW, Mortenson LE.
    JAMA; 1985 Feb 01; 253(5):684-5. PubMed ID: 3918185
    [No Abstract] [Full Text] [Related]

  • 20. Who should subsidize NCI clinical trials?
    Ault A.
    Nat Med; 1998 Sep 01; 4(9):992. PubMed ID: 9734381
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.